Runzhi Zhu

2.0k total citations
31 papers, 1.4k citations indexed

About

Runzhi Zhu is a scholar working on Molecular Biology, Complementary and alternative medicine and Oncology. According to data from OpenAlex, Runzhi Zhu has authored 31 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 11 papers in Complementary and alternative medicine and 8 papers in Oncology. Recurrent topics in Runzhi Zhu's work include Medicinal plant effects and applications (10 papers), Biological Activity of Diterpenoids and Biflavonoids (8 papers) and Natural product bioactivities and synthesis (5 papers). Runzhi Zhu is often cited by papers focused on Medicinal plant effects and applications (10 papers), Biological Activity of Diterpenoids and Biflavonoids (8 papers) and Natural product bioactivities and synthesis (5 papers). Runzhi Zhu collaborates with scholars based in China and United States. Runzhi Zhu's co-authors include Jie Liu, Mingyi Li, Qingyu Zhang, Yajing Wang, Liangqing Zhang, Qinglong Guo, Du Feng, Juan Xia, Bin Liu and Nianping Chen and has published in prestigious journals such as PLoS ONE, Scientific Reports and Food and Chemical Toxicology.

In The Last Decade

Runzhi Zhu

31 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Runzhi Zhu China 22 842 303 232 159 152 31 1.4k
Cuihua Jiang China 26 829 1.0× 145 0.5× 229 1.0× 102 0.6× 186 1.2× 91 1.9k
Yue Jin China 25 881 1.0× 139 0.5× 229 1.0× 174 1.1× 129 0.8× 44 1.8k
Sang Mi Shin South Korea 23 932 1.1× 102 0.3× 320 1.4× 122 0.8× 193 1.3× 35 1.6k
Xia Gong China 29 667 0.8× 299 1.0× 254 1.1× 136 0.9× 456 3.0× 44 1.8k
Xiaobing Dou China 25 752 0.9× 110 0.4× 597 2.6× 209 1.3× 146 1.0× 93 1.7k
Yuanyuan Xie China 17 1.0k 1.2× 162 0.5× 312 1.3× 107 0.7× 164 1.1× 34 1.6k
Hae‐Young Chung South Korea 20 1.3k 1.6× 96 0.3× 194 0.8× 317 2.0× 150 1.0× 34 2.1k
Xuelin Zhou China 22 648 0.8× 308 1.0× 145 0.6× 89 0.6× 396 2.6× 94 1.4k
Jianxia Wen China 21 514 0.6× 185 0.6× 231 1.0× 112 0.7× 400 2.6× 61 1.3k

Countries citing papers authored by Runzhi Zhu

Since Specialization
Citations

This map shows the geographic impact of Runzhi Zhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Runzhi Zhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Runzhi Zhu more than expected).

Fields of papers citing papers by Runzhi Zhu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Runzhi Zhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Runzhi Zhu. The network helps show where Runzhi Zhu may publish in the future.

Co-authorship network of co-authors of Runzhi Zhu

This figure shows the co-authorship network connecting the top 25 collaborators of Runzhi Zhu. A scholar is included among the top collaborators of Runzhi Zhu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Runzhi Zhu. Runzhi Zhu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Huang, Hua, Huibo Lian, Wang Liu, et al.. (2025). Sideroflexin family genes were dysregulated and associated with tumor progression in prostate cancers. Human Genomics. 19(1). 10–10. 1 indexed citations
2.
Zhu, Runzhi, Jingxia Chang, Haixia Xu, et al.. (2021). The Orphan Nuclear Receptor Gene NR0B2 Is a Favorite Prognosis Factor Modulated by Multiple Cellular Signal Pathways in Human Liver Cancers. Frontiers in Oncology. 11. 691199–691199. 9 indexed citations
3.
Chen, Jingnan, Tian Xia, Yanhua Bi, et al.. (2021). Molecular mechanisms and therapeutic implications of dihydromyricetin in liver disease. Biomedicine & Pharmacotherapy. 142. 111927–111927. 42 indexed citations
4.
Liu, Bin, Xiaojie Huang, Yi-Fang Li, et al.. (2019). JS-K, a nitric oxide donor, induces autophagy as a complementary mechanism inhibiting ovarian cancer. BMC Cancer. 19(1). 645–645. 21 indexed citations
5.
Song, Zeqing, Siyuan Hao, Bin Liu, et al.. (2019). JS‑K induces G2/M phase cell cycle arrest and apoptosis in A549 and H460 cells via the p53/p21WAF1/CIP1 and p27KIP1 pathways. Oncology Reports. 41(6). 3475–3487. 9 indexed citations
6.
7.
Liu, Bin, Miaomiao Zhang, Shuna Liu, et al.. (2017). Diosmetin, a Potential p53 Activator, Performs Anticancer Effect by Regulating Cell Cycling and Cell Proliferation in HepG2 Cells. Protein and Peptide Letters. 24(5). 413–418. 5 indexed citations
8.
Yu, Yang, et al.. (2017). Diosmetin Induces Cell Apoptosis by Regulating CYP1A1/CYP1A2 Due to p53 Activation in HepG2 Cells. Protein and Peptide Letters. 24(5). 406–412. 6 indexed citations
9.
He, Yifeng, Juan Duan, Yong‐Guang Yang, et al.. (2017). Expression of Wnt3a in hepatocellular carcinoma and its effects on cell cycle and metastasis. International Journal of Oncology. 51(4). 1135–1145. 22 indexed citations
10.
11.
Zhang, Qingyu, Sheng Ma, Bin Liu, et al.. (2016). Chrysin induces cell apoptosis via activation of the p53/Bcl-2/caspase-9 pathway in hepatocellular carcinoma cells. Experimental and Therapeutic Medicine. 12(1). 469–474. 60 indexed citations
12.
Liu, Jie, Xiaojun Wen, Bin Liu, et al.. (2016). Diosmetin inhibits the metastasis of hepatocellular carcinoma cells by downregulating the expression levels of MMP-2 and MMP-9. Molecular Medicine Reports. 13(3). 2401–2408. 46 indexed citations
13.
Zhang, Qingyu, Tao Fang, Wenhua Hu, et al.. (2015). Notch3 functions as a regulator of cell self-renewal by interacting with the β-catenin pathway in hepatocellular carcinoma. Oncotarget. 6(6). 3669–3679. 44 indexed citations
14.
Yuan, Long, Yongrong Zhang, Juan Xia, et al.. (2014). Resveratrol induces cell cycle arrest via a p53-independent pathway in A549 cells. Molecular Medicine Reports. 11(4). 2459–2464. 73 indexed citations
15.
Zhang, Qingyu, Jie Liu, Bin Liu, et al.. (2014). Dihydromyricetin promotes hepatocellular carcinoma regression via a p53 activation-dependent mechanism. Scientific Reports. 4(1). 4628–4628. 67 indexed citations
16.
Zeng, Guofang, Jie Liu, Hege Chen, et al.. (2014). Dihydromyricetin induces cell cycle arrest and apoptosis in melanoma SK-MEL-28 cells. Oncology Reports. 31(6). 2713–2719. 31 indexed citations
17.
Liu, Jie, Yang Shu, Qingyu Zhang, et al.. (2014). Dihydromyricetin induces apoptosis and inhibits proliferation in hepatocellular carcinoma cells. Oncology Letters. 8(4). 1645–1651. 38 indexed citations
18.
Xia, Juan, Shiwei Guo, Tao Fang, et al.. (2014). Dihydromyricetin induces autophagy in HepG2 cells involved in inhibition of mTOR and regulating its upstream pathways. Food and Chemical Toxicology. 66. 7–13. 49 indexed citations
19.
Liu, Bin, Wei Zhou, Jie Liu, et al.. (2014). Resveratrol inhibits proliferation in human colorectal carcinoma cells by inducing G1/S-phase cell cycle arrest and apoptosis through caspase/cyclin-CDK pathways. Molecular Medicine Reports. 10(4). 1697–1702. 72 indexed citations
20.
Zhu, Runzhi, Guofang Zeng, Qingyu Zhang, et al.. (2013). Oroxylin A Accelerates Liver Regeneration in CCI4-Induced Acute Liver Injury Mice. PLoS ONE. 8(8). e71612–e71612. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cuihua Jiang Breakdown of academic impact, for papers by Yue Jin Breakdown of academic impact, for papers by Sang Mi Shin Breakdown of academic impact, for papers by Xia Gong Breakdown of academic impact, for papers by Xiaobing Dou Breakdown of academic impact, for papers by Yuanyuan Xie Breakdown of academic impact, for papers by Hae‐Young Chung Breakdown of academic impact, for papers by Xuelin Zhou Breakdown of academic impact, for papers by Jianxia Wen
Rankless by CCL
2026